Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics
- 31 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 35 (3), 549-559
- https://doi.org/10.1007/s10557-020-06988-w
Abstract
Purpose DescribeCYP2C19sequencing results in the largest series of clopidogrel-treated cases with stent thrombosis (ST), the closest clinical phenotype to clopidogrel resistance. Evaluate the impact ofCYP2C19genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies. Methods Seventy ST cases on clopidogrel identified from the PLATO trial (n = 58) and Mayo Clinic biorepository (n = 12) were matched 1:1 with controls for age, race, sex, diabetes mellitus, presentation, and stent type. NGS was performed to cover the entireCYP2C19gene. Assessment of exonic variants involved measuring in vitro protein expression levels. Intronic variants were evaluated for potential splicing motif variations. Results Poor metabolizers (n = 4) and rareCYP2C19*8,CYP2C19*15, andCYP2C19*11alleles were identified only in ST cases.CYP2C19*17heterozygote carriers were observed more frequently in cases (n = 29) than controls (n = 18). Functional studies ofCYP2C19exonic variants (n = 11) revealed 3 cases and only 1 control carrying a deleterious variant as determined by in vitro protein expression studies. Greater intronic variation unique to ST cases (n = 169) compared with controls (n = 84) was observed with predictions revealing 13 allele candidates that may lead to a potential disruption of splicing and a loss-of-function effect ofCYP2C19in ST cases. Conclusion NGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism.Funding Information
- National Heart, Lung, and Blood Institute (U01 HL128606)
This publication has 48 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Mutations of POLR3A Encoding a Catalytic Subunit of RNA Polymerase Pol III Cause a Recessive Hypomyelinating LeukodystrophyAmerican Journal of Human Genetics, 2011
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapyAmerican Heart Journal, 2011
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsThe New England Journal of Medicine, 2009
- Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing SignalsJournal of Computational Biology, 2004